Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults.

Valneva (VALN) stock gained as its chikungunya vaccine receives marketing authorization in the U.K., expanding the single-dose shot's global reach. Read more here.

The world’s first chikungunya vaccine, developed by French pharmaceutical firm Valneva SE, has been approved in the UK by the ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in ...

In May last year, the EMA recommended granting a marketing authorization in the EU for Ixchiq, the first vaccine in the EU to protect adults 18 years and older against chikungunya. Dr Rob Hicks is ...

SC Weaver is an inventor on a UTMB patent application describing IRES-attenuated alphavirus vaccines ... in the production of this manuscript. Chikungunya virus (CHIKV) causes an acute febrile ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney disease worsening, kidney failure and cardiovascular disease (CVD) ...

RNA vaccines are composed of the nucleic acid RNA, which encode antigen genes of an infectious agent. When administered to host cells, the RNA is translated into protein antigens that elicit ...

These diseases have a vaccine targeting them which is mandated for school attendance; without a personal belief or religious exemption in four states (California, Connecticut, New York ...

What Are The Emerging Trends In The ixchiq Market? Key trends emerging in the Ixchiq market include the development of a chikungunya vaccine. A notable instance is Valneva SE, a France-based ...